Mark W. Kroll - 24 Jul 2025 Form 4 Insider Report for HAEMONETICS CORP (HAE)

Role
Director
Signature
/s/ Thomas V. Powers, attorney-in-fact for Dr. Kroll
Issuer symbol
HAE
Transactions as of
24 Jul 2025
Net transactions value
$0
Form type
4
Filing time
25 Jul 2025, 16:30:46 UTC
Previous filing
26 Jul 2024
Next filing
12 Nov 2025
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"Mark W. Kroll filed Form 4 for HAEMONETICS CORP (HAE) on 25 Jul 2025."

Quick Takeaways

  • This page summarizes Mark W. Kroll's Form 4 filing for HAEMONETICS CORP (HAE).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Filing timestamp: 25 Jul 2025, 16:30.

What Changed

  • Previous filing in this sequence was filed on 26 Jul 2024.
  • Current net transaction value: $0.

Why This Matters

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Official SEC Source

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
KROLL MARK W Director 125 SUMMER STREET, BOSTON /s/ Thomas V. Powers, attorney-in-fact for Dr. Kroll 25 Jul 2025 0001259254

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HAE Common Stock Award +2,693 +13% 23,357 24 Jul 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.
F2 Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

Sponsored